2025-12-01 10:30 |
Detailed record - Similar records
|
2025-12-01 10:27 |
Detailed record - Similar records
|
2025-12-01 10:24 |
Detailed record - Similar records
|
2025-12-01 10:21 |
Detailed record - Similar records
|
2025-12-01 10:17 |
Detailed record - Similar records
|
2025-12-01 10:12 |
[DZNE-2025-01302]
Journal Article
Yan, S. ; Sahoo, A. ; Zerenner, T. ; et al
Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder
ObjectiveAssess the performance of serum phosphorylated tau 217 (p-tau217) and neurofilament light chain (NfL) in predicting risk of cognitive impairment or phenoconversion to dementia in individuals with iRBD.MethodsWe measured serum p-tau217 and NfL levels by electrochemiluminescence across 4 polysomnographically confirmed iRBD cohorts (n = 300), including individuals who phenoconverted to Parkinson's disease (PD) (n = 51), dementia with Lewy bodies (DLB) (n = 22), and multiple system atrophy (MSA) (n = 5).ResultsSerum p-tau217 levels were increased in individuals with iRBD and cognitive impairment (CI) on testing defined as Montreal Cognitive Assessment <26 or subthreshold parkinsonism. p-Tau217 differentiated individuals with iRBD who developed PD with CI (PD-CI) or DLB from PD phenoconverters with normal cognition (area under curve [AUC] = 0.82; 95% confidence interval, 0.70–0.93) and from iRBD non-phenoconverters with normal cognition (AUC = 0.83; 95% confidence interval, 0.77–0.89) [...]
Detailed record - Similar records
|
2025-12-01 10:08 |
[DZNE-2025-01301]
Journal Article
Hermle, D. ; Schubert, R. ; Barallon, P. ; et al
Digital Outcomes of Upper Limb Ataxia Capture Meaningful Longitudinal Change and Treatment Response
BackgroundDigital-motor outcomes promise better responsiveness than clinician-reported outcomes in ataxia trials. However, their patient meaningfulness and sensitivity to change remain to be demonstrated, particularly in the upper limb domain.ObjectivesValidation of quantitative motor (Q-Motor) assessment for upper limb ataxia against patient-reported outcomes and regarding sensitivity to both longitudinal and treatment-induced change, the latter in n-of-1 treatment settings.MethodsSingle-center longitudinal assessment of finger tapping, diadochokinesia, grip-lift, spiral drawing, and target reaching in (1) 36 cross-genotype ataxia patients and 20 controls, validating digital measures for correlations with patient-reported outcome measure (PROM)-ataxia, 2-weeks test–retest reliability, and sensitivity to change within a trial-relevant 1-year follow-up, anchored in Patient Global Impression of Change (PGI-C); and (2) two patients with spinocerebellar ataxia type 27B (SCA27B) on versus off treatment with 4-aminopyridine.ResultsTwenty-four digital measures correlated with the PROM-ataxia upper-limb composite (|ρ| = 0.4–0.7) and had excellent test–retest reliability (ICC = 0.91–0.99). [...]
Detailed record - Similar records
|
2025-12-01 10:05 |
Detailed record - Similar records
|
2025-12-01 10:00 |
[DZNE-2025-01299]
Journal Article
Vieregge, M. ; Kuzkina, A. ; Janzen, A. ; et al
Dermal Alpha‐Synuclein Aggregation in Seed Amplification Assays for Parkinson's Disease Subtype Differentiation
BackgroundSkin biopsies and seed amplification assays (SAA) provide a sensitive and potentially quantitative method to detect alpha-synuclein (a-syn) aggregation in peripheral nerve fibers in Parkinson's disease (PD). Relating to the previously published hypothesis that PD may either originate in the peripheral (body-first) or central (brain-first) nervous system, we investigated whether patients with clinical features that have been reported to be associated with a suspected body-first subtype of PD exhibit higher levels of a-syn aggregation in dermal nerve fibers compared to those without these features. [...]
OpenAccess: PDF PDF (PDFA);
Detailed record - Similar records
|
2025-11-11 18:10 |
Detailed record - Similar records
|
|
|